693 Spam-Free Article(s) Found
||Eli Lilly and Company
Aug 25, 2015 - Exelixis, Inc. (EXEL) announced that its oncology drug, Cometriq has received Breakthrough Therapy designation from the FDA.
Aug 25, 2015 - Epizyme, Inc. (EPZM) announced that its investigational new drug application for tazemetostat for the treatment of adults and pediatric patients with INI1-negative tumors or synovial sarcoma has been accepted by the FDA.
Aug 24, 2015 - Vital Therapies, Inc. (VTL) announced negative top-line data from the phase III VTI-208 study evaluating the ELAD System in patients with alcohol-induced liver decompensation.